Nebenwirkungen · MabThera
MabThera 100 mg concentrate for solution for infusion MabThera 500 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 17–18
HOS-087546 · Präparat HOS-083527
17 MedDRA Very Common Common Uncommon Rare Very Rare Not known System Organ Class For each term, the frequency count was based on reactions of all grades (from mild to severe), except for terms marked with "+" where the frequency count was based only on severe (≥ grade 3 NCI common toxicity criteria) reactions. Only the highest frequency observed in the trials is reported 1 includes reactivation and primary infections; frequency based on R-FC regimen in relapsed/refractory CLL 2 see also section infection below 3 observed during post-marketing surveillance 4 see also section haematologic adverse reactions below 5 see also section infusion-related reactions below. Rarely fatal cases reported 6 signs and symptoms of cranial neuropathy. Occurred at various times up to several months after completion of MabThera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T15:15:00Z · SHA-256 595c4e1a263e9a34be8b62842a5fc67f95f6a1b1f2a250341444a2960c6c3962 · Passage 1b7d57f5ab5f2abbbd8a3a9179cf36cf18e618a42418a5797e7bc8f960f6b03c · Zeichen 10761–11715 im Abschnitt